PRANA COMPLETES CLINICAL PHASE OF ALZHEIMER'S DRUG TRIAL.Prana Biotechnology Limited's (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PRNAF; ASX ASX See: Australian Stock Exchange : PBT PBT Provider Backbone Transport (networking technology adding determinism to ethernet) PBT Polybutylene Terephthalate PBT Profit Before Tax PBT Paper Based Test (education) ) executive chairman, Geoffrey Kempler, has reported that the company has completed the clinical phase of the its Alzheimer's disease drug trial in Australia. Kempler expressed hope that the landmark trial, the first of several planned by the company, will demonstrate successful "proof of principle" of the company's support of neuroprotection therapies based on oxidation biology and metalloprotein brain chemistry. "This is the first controlled study that has been completed in the world, testing this theory, based on the amyloid protein hypothesis. The human trial results will follow on the compelling animal data that Dr. Ashley Bush and his colleagues reported in the June 2000 issue of Neuron." If successful, Kempler said this would represent "a very significant advance in confirming the cause of Alzheimer's disease, currently a virtually untapped multibillion dollar worldwide market." "We expect to complete analysis of the 36 patient trial in April. The trial was very complex, involving disciplines of neuroscience, psychiatry and neurology. We are pleased that the trial proceeded and finished as scheduled" Kempler stated. This expertise will also be applied in the company's other planned clinical trials. The University of Melbourne
In 2006, Times Higher Education Supplement ranked the University of Melbourne 22nd in the world. Because of the drop in ranking, University of Melbourne is currently behind four Asian universities - Beijing University, , with the Mental Health Research Institute conducted the trial. Collation COLLATION, descents. A term used in the laws of Louisiana. Collation -of goods is the supposed or real return to the mass of the succession, which an heir makes of the property he received in advance of his share or otherwise, in order that such property may be divided, together with the of the data is being conducted by independent experts. Prana, Melbourne, Australia, is currently working on an extensive pipeline of molecules to develop therapeutic drugs to treat a wide range of neuro-degenerative diseases, including Alzheimer's Disease. Professor Colin Masters of the University of Melbourne, Head of the Scientific Advisory Board and Prana Director, along with Drs Ashley Bush and Rudy Tanzi of Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world and Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. collaborated on defining the zinc and copper interaction with amyloid in the brain, which has won substantial acceptance by the international scientific community over the past year. About Prana Biotechnology Limited Based in Australia, incorporated in 1997 and listed on the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. in March 2000, Prana Biotechnology (NASDAQ: PRNAF; ASX: PBT) was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Its mission is to develop therapeutic drugs to treat the central disease pathways that cause degeneration of the brain and eyes as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions including Massachusetts General Hospital, a teaching hospital of Harvard Medical School, and the University of Melbourne. For further information, visit http://www.pranabio.com. For more information, call 212-983-1702 ext. 210 or (Prana) +61 (3) 9690 7892. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion